ENP.AU Entropy Neurodynamics Limited
- Market cap
- AUD 50.7M
- P/E
- -
- P/B
- 6.88x
- ROE
- -66.1%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ENP.AU undervalued?
Graham numberThe Graham number of Entropy Neurodynamics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Entropy Neurodynamics Limited fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-66.1%), below 10%.
ROA 0/1
Return on assets (-58.1%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (19.8%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (6.9x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Entropy Neurodynamics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritab…
Full company profileEntropy Neurodynamics Limited financial statements
Entropy Neurodynamics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | - | - | 99.7K | 619K | 1.12M | 1.59M | - |
| Gross Profit | - | -518.00 | -60.0K | -382K | -1.01M | 99.7K | 619K | -6.77K | -54.3K | -27.3K |
| Operating Income | -565.00 | -219K | -2.31M | -8.00M | -12.7M | -14.1M | -9.59M | -4.97M | -6.73M | -6.77M |
| EBITDA | -565.00 | -174K | -2.22M | -4.90M | -11.7M | -8.27M | -5.10M | -6.70M | -5.27M | -6.74M |
| Net Income | -565.00 | -175K | -2.28M | -5.28M | -8.47M | -10.1M | -7.13M | -6.14M | -5.33M | -4.87M |
| EPS | 0.00 | 0.00 | -0.09 | -0.12 | -0.14 | -0.14 | -0.09 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | - | 308K | 5.40M | 6.54M | 21.5M | 13.6M | 5.88M | 7.45M | 6.66M | 8.38M |
| Total Liabilities | - | 316K | 281K | 1.53M | 2.59M | 4.81M | 1.75M | 1.83M | 699K | 1.02M |
| Shareholders' Equity | - | -7.27K | 5.12M | 5.02M | 18.9M | 8.81M | 4.13M | 5.62M | 5.96M | 7.36M |
| Cash & Short-term Investments | - | 52.4K | 4.42M | 1.74M | 12.7M | 4.85M | 1.64M | 5.37M | 3.03M | 5.58M |
| Total Debt | - | - | - | 913K | 1.36M | 3.74M | 1.53M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | -93.9K | -2.18M | -6.72M | -7.89M | -8.59M | -4.03M | -6.00M | -7.77M | -3.41M |
| Capital Expenditure | - | 21.0K | 534K | 632K | 1.63M | 1.13M | 4.00 | 2.00 | 133K | 5.57K |
| Free Cash Flow | - | -115K | -2.72M | -7.35M | -9.51M | -9.72M | -4.03M | -6.00M | -7.90M | -3.41M |
| Ratios | ||||||||||
| ROE | - | - | -44.6% | -105.2% | -44.9% | -114.5% | -172.8% | -109.3% | -89.4% | -66.1% |
| ROA | - | -56.6% | -42.3% | -80.7% | -39.5% | -74.1% | -121.2% | -82.4% | -80.0% | -58.1% |
| Net Profit Margin | - | - | - | - | - | -10,111.3% | -1,152.7% | -548.7% | -335.9% | - |
| Debt to Equity | - | - | - | 0.18x | 0.07x | 0.42x | 0.37x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Entropy Neurodynamics Limited dividends
Entropy Neurodynamics Limited has not paid dividends in the last 9 fiscal years.
Last stock split: 1:2.5 on Apr 15, 2024.
Who owns Entropy Neurodynamics Limited
- Insiders 32.81%
- Institutions 6.96%
- Public & others 60.23%
- Shares outstanding 1.63B
- Free float 1.20B
Entropy Neurodynamics Limited company profile
- Company name
- Entropy Neurodynamics Limited
- Ticker
- ENP.AU
- ISIN
- AU0000433583
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Bio101 Financial Advisory Pty Ltd, Hawthorn East, VIC, Australia, 3123
- Phone
- 61 3 9092 0475
- Website
- entropyneurodynamics.com
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. In addition, it is pursuing Phase 2 clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Hawthorn East, Australia.
Entropy Neurodynamics Limited management
6- Mr. Jason Alan CarrollMD, CEO & Executive Director
- Dr. James P. Gilligan MSIB, Ph.D.President & Chief Scientific Officer · born 1952
- Mr. Christopher Leo NtoumenopoulosExecutive Director · born 1983
- Mr. Hamish George B.Com., C.A.CFO & Company Secretary
- Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.Chief Medical Officer · born 1948
- Ms. Meghna PiplaniJoint Company Secretary